Close Menu

Breaking News

Regular SARS-CoV-2 testing could limit COVID-19 cases on university campuses but results might vary based on the schools' behavioral interventions.

According to the company, the test has shown to be more sensitive and accurate than a COVID-19 anterior nasal swab test in the firm's EUA validation study.

The seven technologies feature different methods, including CRISPR and microfluidics, and can be performed in many settings and with a variety of sample types.

The test, which has Emergency Use Authorization from the US Food and Drug Administration, is designed to detect the SARS-CoV-2 ORF1ab, N, and E genes.

In a local coverage article, Medicare contractors in the MolDx program added prostate cancer to the covered indications for the test.

The firm saw $109 million in sales of its COVID-19-related products, including nearly $53 million in sales of its Lyra SARS-CoV-2 molecular diagnostic assay.

The company is employing Guardant360 in a Phase III trial assessing the efficacy of the drug both in a larger population and in women who test positive for ESR1 mutations.

For the three months ended June 30, the genomic testing firm reported total revenues of $20.7 million.

The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

Researchers have developed a method, called MemorySeq, to identify genes transcriptome-wide whose expression fluctuations persist for several cell divisions.

SomaLogic will analyze more than 40,000 samples, including from Amgen clinical trials, using its SomaScan platform, which measures up to 5,000 proteins.

The agency has provided new guidance for tests that can be used outside of a lab setting, as well as updated its guidance on a number of other topics.

PharmaCyte licensed the RT-PCR and enhanced fluorescence RT-PCR tests from Hong Kong-based Hai Kang Life.

Strong demand for the firm's COVID-19 molecular tests for the Panther and Panther Fusion platforms offset revenue declines in other areas of the business.

With revenues of $143,000, the company incurred a net loss of $9.1 million, or $0.14 per share, for the quarter, exceeding the consensus Wall Street estimate.

The firm added $50 million from Casdin Capital, Danaher Life Sciences, and Agilent Technologies to its $38.5M Series B round announced in May 2019.

The group will use Akoya's Phenoptics platform to discover biomarkers for selecting neoadjuvant and adjuvant immunotherapies for early-stage breast cancer patients.

In more than a dozen new papers, ENCODE researchers reported on analyses of the human and mouse genomes, using new data types and additional tissues.

Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway.

The collaboration seeks to develop RNA-based signatures that could help oncologists predict disease progression and guide the use of precision therapies.

MaviDx will develop, validate, secure regulatory approvals for, and commercialize its SARS-CoV-2 and other infectious disease tests, including for influenza, on Veracyte's nCounter system.

Pages

According to the Wall Street Journal, the Food and Drug Administration may soon issue an Emergency Use Authorization for convalescent plasma to treat COVID-19 patients.

Minnesota police have used genetic genealogy to make an arrest in a 1986 cold case, reports NBC News.

Researchers have used CRISPR-Cas9 to efficiently target a cephalopod pigmentation gene, as they report in Current Biology.

In Science this week: chromatin accessibility of microglia during fetal development, and more.